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Monoclonal gammopathyeassociated peripheral neuropathy must be differentiated from 2 other well-characterized plasma cell disorders that cause neuropathy and have strict diagnostic criteria, namely immunoglobulin light chain (AL) amyloidosis and neuropathy associated with osteosclerotic myeloma (POEMS [polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes] syndrome) (Table) . 1 In AL amyloidosis neuropathy and in POEMS syndrome, the causal relationship between the neurologic process and the underlying M protein is not in question, and therapy is aimed at the underlying disorder. These entities are reviewed in detail elsewhere.
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EPIDEMIOLOGY Peripheral neuropathy can occur in patients across the spectrum of plasma cell disorders from the premalignant MGUS stage to the overt malignant stages of MM and WM. In order to understand the epidemiology of monoclonal gammopathyeassociated peripheral neuropathy, one needs to appreciate that MGUS is relatively common in the general population and that the mere presence of an M protein in a patient with neuropathy does not mean that a causal relationship exists. In fact, more often than not the association is probably coincidental, simply reflecting the relatively high prevalence of these 2 disorders in the population.
Monoclonal gammopathy of undetermined significance is present in more than 3% to 4% of the population older than age 50 years. 5 It is a premalignant precursor of MM. There are 3 major types of MGUS depending on the type of M protein secreted: IgM MGUS, non-IgM MGUS (includes IgG MGUS and IgA MGUS), and light-chain MGUS. Progression to malignant disease is the main clinical consequence of MGUS and occurs at a rate of 1% per year. 6 IgM MGUS is associated with a risk of progression to WM, while non-IgM MGUS carries a risk of progression to MM. Light-chain MGUS is a newly discovered entity that is associated with a risk of progression to light-chain type of MM. All forms of MGUS can progress to AL amyloidosis. The other main consequence of MGUS is the ability to cause organ damage due to the immunogenic properties of the M protein including peripheral neuropathy, membranoproliferative glomerulonephritis, and necrobiotic xanthogranuloma. The association of MGUS with neuropathy has been confirmed in a population-based screening study of 17,398 persons living in Olmsted County, Minnesota, 605 with MGUS and 16,793 negative controls. 7 With a mean follow-up of 24 years, totaling 14,373 person-years, there was a significantly higher risk of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Given the prevalence of MGUS, neuropathy associated with an M protein is frequently encountered in clinical practice. In a series of 132 patients with monoclonal gammopathy, 4 (3%) had peripheral neuropathy. 8 In another study, Isobe and Osserman 9 found peripheral neuropathy in approximately 5% of patients with a plasma cell dyscrasia of unknown significance. Other studies have found a statistically significant increase in the prevalence of M proteins in patients with peripheral neuropathy compared with normal populations in Minnesota, France, and Sweden. 10 Overall, these studies suggest that an M protein can be detected in approximately 3% to 5% of all cases of peripheral neuropathy, especially in patients referred to tertiary care centers with such symptoms. Among patients with peripheral neuropathy in whom no cause is apparent, the prevalence of an M protein may be as high as 10%. 10 Approximately half of these associations are likely coincidental, since MGUS is prevalent in 3% to 4% of the normal adult population over 50 years of age. 5 The remaining associations may be causally related to the underlying M protein.
An even greater number of patients with MM or WM may have symptoms of peripheral neuropathy that are present at diagnosis or occur during the course of the disease. As with MGUS, some of these associations are likely coincidental, whereas others may be causally related to the underlying M protein.
Further, in patients with MM and WM, another factor that should be considered is that drugs used to treat these disorders may be neurotoxic and may be the true cause of the symptoms.
The type of M protein in monoclonal gammopathyeassociated peripheral neuropathy is most commonly IgM, while IgG or IgA neuropathies are less common. 11 In one study, approximately 60% of neuropathies associated with monoclonal gammopathy were IgM, 30% were IgG, and 10% were IgA. 12 IgM M protein appears to be associated with a higher predilection for causing peripheral neuropathy compared with IgG or IgA MGUS. 13 In a study of 74 patients with MGUS, 8 of 26 patients with IgM MGUS (31%) had neuropathy, compared with 2 of 34 patients with IgG MGUS (6%) and 2 of 14 with IgA MGUS (14%). 13 
PATHOPHYSIOLOGY
The pathophysiology of monoclonal gammopathyeassociated peripheral neuropathy is not well understood.
14 Pathologic studies in WM-and IgM MGUS-associated neuropathy have identified demyelination and widened myelin lamellae. 11, 15 Monoclonal IgM deposits can be detected in the widened lamellae of myelin fibers and in myelin debris contained in Schwann cells and macrophages. 16 Demyelination was also noted in a study of 5 patients with IgG MGUSe associated peripheral neuropathy; in 3 patients there was "onion bulb" formation, which is caused by concentric layers of Schwann cell cytoplasm and connective tissue around an axon believed to be caused by repeated demyelination and remyelination. 17 The reactivity of M proteins in peripheral neuropathy has been best studied in IgM disorders. In about 40% to 50% of patients with IgM monoclonal gammopathyeassociated neuropathies, the M protein binds to myelinassociated glycoprotein (MAG). 11, 18, 19 In the subset of patients with IgM monoclonal gammopathyeassociated peripheral neuropathy who do not have anti-MAG antibodies, a recent cohort study of 54 patients found antiganglioside antibodies in 35% of patients and antibodies against ganglioside complexes in 9%. 18 Most of the patients with antiganglioside or antieasialo GM1 antibodies had sensory and motor symptoms, but no clear relationship was found between the antibody specificity and clinical characteristics. 18 No major differences have been found comparing the clinical presentation of IgM-related neuropathies based on the antibody specificity (ie, anti-MAG, antiganglioside, or antieasialo GM1).
The pathogenesis is thought to be a direct effect of M proteins on the peripheral nerve, resulting in a demyelinating process. A study of 25 patients with WM and neuropathy found that among all the cases in which the IgM had activity against myelin, patients experienced neuropathy symptoms at presentation. 20 Among 7 of the 15 patients in whom the IgM M protein did not have reactivity against myelin, neuropathic symptoms developed 1 to 5 years after the initial diagnosis of WM. In another study of 24 patients with IgM MGUS who were asymptomatic at initial evaluation, higher titers of anti-MAG antibodies were associated with the development of neuropathy symptoms. 21 These studies suggest that a likely causal relationship between the M protein and peripheral neuropathy exists in at least a subset of cases. However, anti-MAG antibodies are not specific and have also been detected in patients with IgM AL amyloidosis and neuropathy. 22 Further, reduction in anti-MAG antibodies with rituximab therapy has not correlated with clinical improvement, so more research is needed on the mechanisms of nerve damage.
CLINICAL PRESENTATION
Peripheral neuropathy is much more commonly associated with IgM M proteins than with IgG or IgA M proteins. In fact, it is not clear whether there is a true causal relationship between non-IgM M proteins and peripheral neuropathy, except in patients with POEMS syndrome or AL amyloidosis. Additional studies in this regard are needed. Clinically, it is hard to distinguish monoclonal gammopathyeassociated peripheral neuropathy from other causes of neuropathy. There are some differences in the clinical presentation of neuropathy-associated IgM M proteins compared with that reported to be associated with IgG or IgA M proteins. 23 In general, IgM monoclonal gammopathye associated peripheral neuropathy presents as distal, acquired, demyelinating, symmetric neuropathy with M protein (DADS-M). 24, 25 It typically affects men in their sixth to ninth decade of life as a distal, symmetric neuropathy that affects primarily large sensory nerve fibers, causing sensory ataxia. 26 Motor involvement can occur and is typically mild and distal. Cranial nerve involvement is rare but can occur. Anti-MAG antibodies are present in approximately 50% of patients; however there is no difference in the severity or type of neuropathy with or without anti-MAG antibodies. 27 In contrast, non-IgM monoclonal proteins can be seen in the full spectrum of neuropathy phenotypes from the more common lengthdependent sensorimotor axonal peripheral neuropathy to classic CIDP (predominantly motor with proximal and distal involvement). 28 A Mayo Clinic study of 65 patients with MGUS and peripheral neuropathy found no significant clinical differences between the patients with IgG MGUS (n¼24) and those with IgA MGUS (n¼10). 27 Patients with IgG MGUS can have antibodies against neural antigens, even in the absence of clinical neuropathy. [28] [29] [30] Furthermore, in patients with CIDP, those with and without a paraprotein respond similarly to treatment. 31 For all of these reasons, the finding of an IgG or IgA monoclonal gammopathy, unless found in conjunction with POEMS syndrome or AL amyloidosis, may be coincidental and less likely to be causally related to peripheral neuropathy.
There are common electrophysiologic features in DADS-M that suggest demyelination, including slowed motor conduction velocities, markedly prolonged distal latencies, and low terminal latency indices, all implying involvement of the terminal nerves. The sensory responses are typically reduced or absent. 27, 32 In comparison to patients with IgG, these findings are all worse in those with IgM and are suggestive of demyelination, whereas the IgG group typically has axonal findings. However, rare patients have findings seen in classic CIDP and motor neuropathy with conduction block. 33 
DIAGNOSIS
Monoclonal gammopathyeassociated peripheral neuropathy should be considered when an M protein is detected during work-up of unexplained neuropathy. The first step in evaluation is to determine if the monoclonal gammopathy is the likely cause of peripheral neuropathy or if it is a coincidental finding related to the frequency with which M proteins are seen in the general population ( Figure 1 ). Other explanations and causes of peripheral neuropathy such as genetic characteristics, diabetes mellitus, alcoholism, and drugs must be considered first and excluded as much as possible. There are no specific tests to distinguish between a true causal association and an incidental one. In general, the younger the patient, the more likely that the association is causal because the prevalence of M proteins in persons younger than 50 years is less than 1.5%. In contrast, the prevalence of M proteins is as high as 7% in persons older than 70 years, and thus, many associations are likely coincidental. Similarly, the likelihood of a causal relationship is far higher with IgM M proteins than with IgG or IgA M proteins. Other laboratory studies are not as useful. Anti-MAG antibodies can be detected in approximately 50% of patients with IgM M proteinerelated peripheral neuropathy. Although this frequency may suggest a causal relationship, the specificity is low.
The next step in the evaluation is to differentiate monoclonal gammopathyeassociated peripheral neuropathy from specific plasma cell disorders that are known to have a definite causal relationship, namely POEMS syndrome and amyloid neuropathy. In patients with POEMS syndrome and AL amyloidosis, the overall approach and nature of treatment is different.
Next, the nature of the underlying monoclonal gammopathy must be determined. Most patients with an M protein will have MGUS, but some will have MM or WM. These disorders must be excluded by bone marrow studies to determine the proportion of clonal cells and imaging studies to rule out osteolytic bone lesions, lymphadenopathy, or organomegaly. 1, 34 Patients with WM or MM need systemic therapy for the underlying malignant disease regardless of the severity of the neuropathy. In these patients, if there is improvement in neuropathy as the malignant disorder is treated, it can be assumed that a causal relationship is likely.
Finally, one must assess and document the severity of the neuropathy. The severity of the neuropathy and progression over time are major determinants of whether therapeutic intervention targeting the M protein is needed. This determination is mainly based on history and physical examination. Nerve conduction and electromyographic studies can be particularly helpful if they reveal the typical findings in DADS-M as well as providing information on severity of the neuropathy and serving as a baseline for future comparison, especially if treatment is considered.
DIFFERENTIAL DIAGNOSIS
When M proteins are found in the setting of peripheral neuropathy, POEMS syndrome and AL amyloid neuropathy must be considered in the differential diagnosis because the pathogenesis and treatment of these disorders are different.
POEMS Syndrome
POEMS syndrome is a clonal plasma cell disorder described by the components of its This group includes patients with multiple myeloma who have concurrent peripheral neuropathy. These patients require therapy to eradicate the neoplastic clone because of the nature of the malignant disorder in contrast to patients with monoclonal gammopathy of undetermined significance in whom establishing a causal relationship between neuropathy and the monoclonal protein is critical for therapeutic purposes. POEMS ¼ polyneuropathy, osteosclerotic myeloma, endocrinopathy, monoclonal protein, and skin changes.
name, polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes. 4 POEMS syndrome is characterized by a progressive chronic demyelinating sensorimotor polyneuropathy that is either length dependent or a polyradiculoneuropathy and is often mistaken for CIDP. Organomegaly (hepatomegaly or splenomegaly) and skin changes (eg, hyperpigmentation) can be seen. Other characteristics include edema, pleural effusions, ascites, and papilledema. 4 The bone lesions in POEMS syndrome are sclerotic (osteosclerotic myeloma) in contrast to MM, in which bone lesions are osteolytic. Many patients with POEMS syndrome may present mainly with neuropathy and a l type M protein, with the other features not being prominent. Careful evaluation with history and physical examination is needed, and if POEMS is suspected, radiologic (skeletal survey or computed tomography) studies looking for one or more osteosclerotic bone lesions should be performed.
The peripheral neuropathy is motor predominant but with associated sensory symptoms and often pain at initial presentation. 35, 36 The histologic pattern usually represents axonal degeneration along with demyelination. Electromyography usually reveals a demyelinating pattern with more severe axonal loss (reduction of motor amplitudes and increased fibrillation potentials) than seen in CIDP or DADS-M. The M protein in POEMS syndrome is usually IgG or IgA. The underlying cause of the neuropathy remains unknown, although vascular endothelial growth factor may play a role in pathogenesis. 37 Treatment of POEMS syndrome involves radiation and chemotherapy for the sclerotic plasmacytomas, 11 which usually results in significant clinical improvement of the neuropathy as well as the other systemic features. 38 
AL Amyloid Neuropathy
Peripheral neuropathy occurs in 15% to 20% of patients with AL amyloidosis; however, neuropathy is the dominant presentation of the disease among only 25% of such patients. 3 The possible mechanisms of neuropathy in AL amyloidosis are direct effect of amyloid deposition in the nerves, nerve compression, or ischemia. 39 The neuropathy is often length dependent and associated with burning, pain, and numbness. Upper limb involvement is common, often due to superimposed carpal tunnel syndrome. The neuropathy in AL amyloidosis often has an axonal pattern, whereas monoclonal gammopathy (IgM)eassociated peripheral neuropathy is primarily demyelinating in nature. Autonomic function also tends to be impaired in neuropathy associated with AL amyloidosis. Compared with MGUS-associated neuropathies, which can have an extended stable period, in patients with dominant AL neuropathy, the clinical course is more progressive and debilitating. 3 
PROGNOSIS
Approximately 25% to 30% of patients with IgM monoclonal gammopathyeassociated peripheral neuropathy have moderate disability at 10 years after diagnosis. 40 In a study of 26 patients with high-titer anti-MAG IgM neuropathy, a favorable prognosis was seen in most patients after a mean follow-up of more than 8 years. 41 The disability rates at 5, 10, and 15 years from onset of neuropathy were 16%, 24%, and 50%, respectively. It is more difficult to estimate the prognosis of non-IgMerelated neuropathy because in most studies it is difficult to ascertain whether the monoclonal gammopathy was causal or coincidental.
TREATMENT Unfortunately, there are very limited data to guide clinical practice in patients with monoclonal gammopathyeassociated peripheral neuropathy. Further, most treatment results have been disappointing. In many patients, the treatments used can be more risky or cumbersome than the peripheral neuropathy. When considering therapy, it is important to recognize that most associations of neuropathy and M proteins are coincidental. If the M protein is not of the IgM type, data on causal association with neuropathy and treatment efficacy are very limited. In order to consider any type of intervention, there must be high probability that the neuropathy is secondary to the monoclonal gammopathy. Other causes of neuropathy and other monoclonal plasma cell disorders that cause neuropathy (POEMS syndrome, AL amyloidosis) must have been considered and excluded. Finally, the peripheral neuropathy should be considered to be severe and progressive enough to warrant therapy. An approach to the treatment of monoclonal gammopathyeassociated peripheral neuropathy is provided in Figure 2 . The results of studies evaluating treatments for monoclonal gammopathyeassociated peripheral neuropathy are discussed in the subsequent sections.
Intravenous Immunoglobulin
Various studies have reported limited short-term benefit of treatment with human intravenous immunoglobulin (IVIG) in IgM monoclonal gammopathyeassociated peripheral neuropathy. 11 The mechanism of action is not well understood; it may be related to a neutralization of anti-MAG antibodies or to an antibody response to the anti-MAGeproducing CD5-positive B cells. 42 Intravenous immunoglobulin was suggested as a treatment option in 1990 by Cook et al 43 because of its efficacy in treating myasthenia gravis, Kawasaki disease, CIDP, and polymyositis. The authors conducted an uncontrolled study of 2 patients with demyelinating neuropathies; one case was associated with an antiganglioside IgM gammopathy and the other with an anti-MAG IgM gammopathy. The patients reported no benefit from previous treatments including prednisone, chlorambucil, azathioprine, and plasmapheresis. Initial improvement in strength was seen in each patient at least 8 days after treatment with high-dose IVIG and was sustained with continued high-dose treatment.
A subsequent study of IVIG in 13 patients with IgM neuropathy and 4 with IgG neuropathies found limited benefit. 44 Intravenous immunoglobulin was administered in a dose of 2 g/kg every 4 weeks for a period ranging from 3 months to 3 years. Among 7 patients with IgM M proteins who had no benefit from prior immunosuppressive treatment, 4 experienced some improvement in neurologic scores but no change in IgM levels or antibody response. Among 3 of the patients with no prior treatment, 2 had substantial Unlikely that M protein is causally related to neuropathy; most associations are likely coincidental. CIDP ¼ chronic inflammatory demyelinating polyneuropathy (predominantly motor neuropathy with proximal and distal involvement); DADS ¼ distal, acquired, demyelinating, symmetric neuropathy (mainly distal, sensory neuropathy); IVIG ¼ intravenous immunoglobulin. improvement in neurologic scores. Among patients considered to have IgG neuropathy, 2 with axonal neuropathy had no benefit, while 2 patients with chronic demyelinating polyneuropathy had a clinical response to treatment. In a study of 33 patients with anti-MAG IgMeassociated neuropathies, short-term improvement was noted in 6 of 17 patients (35%) treated with IVIG and objective benefit with increased ability and strength for activities of daily living in 4 (24%). 45 No change in serum IgM levels or electrophysiologic study results was seen with treatment. In this study, plasmapheresis and prednisone had no significant effect. These open-label single-arm studies have limitations but suggest that IVIG may produce some limited benefit in patients with IgM monoclonal gammopathyeassociated peripheral neuropathy.
In a randomized, double-blind study, 11 patients with IgM demyelinating polyneuropathy received either placebo or IVIG for a 3-month period and then the opposite treatment for 3 months after a washout period. 46 The investigators assessed muscle strength as well as sensory and neuromuscular symptoms using the Medical Research Council (MRC) scale. None of the 4 patients treated initially with placebo had significant improvement (MRC score increase by 10 or more points) in these parameters during either the placebo or the IVIG phases of their treatment. Two of the 7 patients in the initial IVIG group had improvements in strength and neuromuscular symptoms that affected their activities of daily living. These improvements regressed during the placebo phase. Mariette et al 47 compared IVIG (2 g/kg and then 1 g/kg every 3 weeks) vs recombinant interferon-alfa (3 MU/m 2 subcutaneously 3 times weekly) in 20 patients with polyneuropathy associated with an IgM M protein. Only 1 of 10 patients assigned to IVIG had improvement compared with 8 of 10 patients treated with interferon-alfa; however, a subsequent study found no benefit with interferonalfa. 48 More promising results were seen with IVIG in a randomized double-blind crossover trial, with 10 of 22 patients (45%) experiencing improvement during therapy with IVIG compared with 4 of 22 (18%) during the placebo treatment period. 49 Overall, these studies indicate a modest potential short-term benefit of IVIG in patients with IgM neuropathies. Data on the role of IVIG in patients with non-IgM monoclonal gammopathy is even more limited. A retrospective study of IVIG treatment in 20 patients with polyneuropathy associated with IgG gammopathy suggested an improvement among 8 patients (40%), as evaluated by an increase in MRC strength and sensory scores and Rankin disability scale scores. 50 Six patients experienced a decline after the initial improvement and therefore required additional therapy; the other 2 patients had sustained improvement after the initial course. The patients who responded to IVIG had shorter symptom duration at baseline assessment, more symptoms of numbness, more falling episodes, and more proximal leg weakness before therapy compared with patients who did not respond. The investigators found that these clinical features were more consistent with demyelinating neuropathies. Because this study was retrospective, we cannot determine how convinced the treating physicians were about a causal association.
Plasmapheresis
Treatment with plasmapheresis (also known as plasma exchange) has produced conflicting results. The rationale is to remove the offending M protein and thereby reduce ongoing target antibodyemediated injury to neuronal fibers. 31 Initial case reports supported the potential for application of plasmapheresis for treatment of non-IgM (IgG and IgA) neuropathies, with sensory symptoms and strength improving with treatment. 51, 52 Some of these patients experienced relapses without plasmapheresis that were reversible with continued treatment or increased frequency of exchange. Based on the clinical course, it is likely that these relapses probably occurred in patients with CIDP in whom the M protein was an incidental abnormality causally unrelated to the clinical symptoms.
In a double-blind trial of 39 patients with neuropathies associated with IgG, IgA, or IgM MGUS, patients were randomized into sham plasmapheresis or true plasmapheresis twice per week for 3 weeks. 31 Patients who were assigned to the sham group eventually received plasmapheresis in an open-label trial.
Although the overall differences in response to sham or true plasmapheresis were not significant, the sham exchange group had an average decrease of 2 points on neuropathy disability score, whereas the plasma exchange group had an average decrease of 12 points. Comparing IgG or IgA gammopathies to IgM gammopathy, patients with IgG-or IgArelated neuropathy had greater improvement in average weakness scores than those with IgM-related neuropathy in both the doubleblind and open trials. The results of this study must be taken in context of the fact that some non-IgMerelated neuropathies may represent CIDP with incidental unrelated M proteins and that plasmapheresis has benefit in CIDP regardless of an association with monoclonal gammopathy. Nevertheless, the study provides rationale for a different approach to therapy based on the type of the M protein ( Figure 2 Clinical neuropathy disability scores (CNDSs) after 12 months were used to assess efficacy. No significant difference was found between the average CNDS decrease in the chlorambucil alone group (2.1-point decrease) and the chlorambucil plus plasma exchange group (1.8-point decrease). In both treatment groups, only the sensory component of the CNDS contributed to the improvement. By the end of the study, there was an improvement in neuropathy among 15 patients, 8 from the chlorambucil alone group and 7 from the combined treatment group, after treatment. The neuropathy remained stable or worsened in the remaining patients. Overall, the study results indicate that plasmapheresis provides no additional benefit to chlorambucil treatment for IgM monoclonal gammopathyeassociated peripheral neuropathy.
Fludarabine
The purine nucleoside analogue fludarabine has long been used for the treatment of WM. Based on those data, fludarabine was studied in patients with IgM-related neuropathy. 54 The goal was to eradicate the clone that produces IgM. The study included 4 patients, 1 of whom was ultimately diagnosed as having WM. Intravenous fludarabine (25 mg/m 2 ) was administered for 5 days every 4 to 6 weeks for 5 to 6 months. Three of the 4 patients treated had previously received treatment with other therapies including corticosteroids, plasmapheresis, and IVIG, with minimal improvement in signs or symptoms. In all of the cases, both subjective and objective improvement occurred. Objective improvements were assessed by sensory scores, timed walking, and disability scores using the Rankin scale. There was also a decrease in IgM concentration by 25% or more in 3 of the 4 patients. The investigators found no difference in response to fludarabine between the patients with or without anti-MAG antibodies. Although this study was a small case series, its results suggest that fludarabine (and possibly other methods targeting the underlying neoplastic clone) may be a useful treatment for IgM monoclonal gammopathyeassociated peripheral neuropathy refractory to other treatment methods. Further study of fludarabine and its clinical effects on IgM neuropathy is warranted.
Rituximab
There have been a number of pilot studies and case reports on the treatment of IgM-related neuropathy with the anti-CD20 monoclonal antibody rituximab, which targets the underlying clonal population. 11, 55 The treatment protocol in most of these studies was weekly infusions of 375 mg/m 2 of rituximab over 4 weeks. [55] [56] [57] [58] The results of these studies suggested a limited beneficial effect in some patients. Case studies have reported decreased IgM levels in IgM monoclonal gammopathye associated neuropathy and improvement of neuropathy in cases of anti-MAG/sulfated glucoronyl paraglobosideeassociated WM with rituximab treatment. 56, 58 There have also been case reports of a neuropathy flare in WM following rituximab therapy. 59, 60 A prospective study of 10 patients with anti-MAG IgM-related neuropathy found that all patients had improvement with regard to sensory ataxia and muscle strength at 12 months, 8 maintained improvement at 24 months, and 6 sustained improvement at 36 months. 61 Patients who did not experience improvement had a slow and progressive increase in ataxia and weakness that led to a decline in gait function. The study on the long-term effect of rituximab also revealed significant median reduction in anti-MAG antibody titers by 93% at 12 months, by 80% at 24 months, and close to 60% at 36 months. In a pilot study of 5 patients with anti-GM1 or anti-MAG IgM neuropathy, all 5 patients had an increase in strength, both subjectively and objectively, 3 to 6 months after treatment with rituximab. 62 An average of 47% reduction in IgM autoantibody titers was seen in 3 patients at 6 months.
A nonrandomized comparative study monitored strength and antibody levels in 21 patients with IgM polyneuropathies treated with rituximab and 13 untreated controls over the course of 2 years. 63 Patients had either antiganglioside (GM1 or Ga1NAc-GD1) or anti-MAG IgM-positive neuropathies. Quantitative strength was tested bilaterally by dynamometry, with 12 measurements every 6 months; changes by 12% or more of normal were significant (P<.05). None of the untreated patients had significant improvement in strength, whereas strength improved by at least 12% among 18 of the 21 treated patients (86%). The mean change in strength among treated patients at 1 year was 13% and at 2 years was 23%. No change in total antibody or levels directed against antigens was found among the untreated patients. Among treated patients, total IgM levels decreased to 74% of initial values at 1 year and to 55% of baseline values at 2 years.
Two randomized controlled trials have been conducted to assess the efficacy of treatment of anti-MAGepositive IgM neuropathy with rituximab. In one study, a total of 26 patients were studied comparing rituximab vs placebo (13 patients in each group). 55 Patients selected had a demyelinating neuropathy, an IgM monoclonal protein, anti-MAG/ sulfated glucoronyl paragloboside antibodies, and diminished function as measured by an Inflammatory Neuropathy Course and Treatment (INCAT) disability score greater than or equal to 1. Improved INCAT scores were seen in 4 of the patients receiving rituximab (31%) over 8 months, whereas no improvement or worsening was seen in patients receiving placebo. Improvement began at 3 months in those who experienced improvement but was sustained at 6 months to a year after treatment. IgM levels decreased by 34% and MAG antibody titers were reduced by 50% at 8 months after treatment in the rituximab group.
In another double-blind, placebocontrolled trial, 54 patients with anti-MAG IgM chronic demyelinating neuropathy were randomized to receive either placebo or rituximab. 57 Patients selected had an INCAT sensory score (ISS) above 4, a visual analog pain scale score above 4, or an ataxia score greater than 2. The primary outcome of absolute improvement in ISS from baseline at 12 months was not achieved in the study because no significant difference in the change in ISS was seen between rituximab and placebo groups. However, secondary outcomes were achieved with 20% of patients in the rituximab group having improvement of at least 2 points on the INCAT disability scale, whereas none in the placebo group had improvement. Overall, the authors concluded that rituximab was not effective for improvement in ISS in patients with anti-MAG IgM demyelinating neuropathy but that dosing regimens and combination therapies with rituximab remain an area for further study.
Further study of rituximab treatment through placebo-controlled trials with larger sample sizes are needed to elucidate the efficacy of rituximab treatment for IgMassociated neuropathies.
APPROACH TO THERAPY
As discussed, data on which to base definitive treatment recommendations are very limited. In patients with overt WM or MM who require therapy for the underlying malignant disease, the treatment of the underlying disease will be the primary approach. Symptomatic treatments can be administered as needed. Some care should be made in selection of agents for treatment of the malignant disorder in order to avoid drugs with known neurotoxic potential as much as possible.
Our approach to the treatment of monoclonal gammopathyeassociated peripheral neuropathy is provided in Figure 2 . Most treatment results have been disappointing, and studies testing the value of newer treatments used in WM, such as ibrutinib, are needed in patients with IgM monoclonal gammopathyeassociated peripheral neuropathy. In patients with IgM monoclonal gammopathyeassociated peripheral neuropathy who have severe refractory or progressive neuropathy after treatment with IVIG and rituximab, a decision on further treatment should be made with care. In many instances, these patients may need to be managed with symptomatic methods. Further consideration should be given to other causes of neuropathy. If the patient understands the risks and the neuropathy is severe or disabling, one could consider treatments used in WM on a caseby-case basis (Figure 1 ). These regimens include rituximab plus bendamustine, ibrutinib, and fludarabine. The patient must be advised that these treatments carry long-term risks and that they may be more toxic or cumbersome than the peripheral neuropathy.
Non-IgMerelated peripheral neuropathy presenting with features similar to CIDP should be treated as CIDP with treatments such as plasmapheresis, IVIG, and prednisone as warranted by the severity of the symptoms. A causal relationship should generally not be considered in patients with non-IgM M proteins who have peripheral neuropathy with features that do not resemble CIDP. In most of these patients, the relationship between the M protein and neuropathy is likely coincidental, and there is greater potential for harm with therapy.
CONCLUSION
Additional studies investigating new options for therapy are needed. We recognize that many patients have disabling symptoms, and as new treatments emerge for malignant plasma cell disorders, some of these treatments can be translated to the treatment of severe monoclonal gammopathyeassociated peripheral neuropathy. We need a better understanding of the pathophysiologic mechanisms of the disease and better biomarkers to assess the value and effectiveness of therapy. Further studies are also needed to determine if there is a true association between nonIgM monoclonal gammopathy and peripheral neuropathy. The Symposium on Neurosciences will continue in an upcoming issue.
